Consumers’ vaccine skepticism persists: Their growing distrust coupled with the spectre of RFK Jr. leading the HHS could portend bad news for Big Pharma

President-elect Donald Trump's second term promises profound shifts across commerce, technology, and regulation that will reshape how businesses operate and consumers behave. As the president-elect prepares to take office, his policy priorities are already triggering market reactions and pivots from major corporations.

Lawmakers criticize HHS plan to regulate healthcare AI: Their position stands in stark contrast to physicians, who could refuse to use the tech if it’s not properly vetted.

Trump’s healthcare picks will look to rein in GLP-1 spending: His selections to run the FDA and HHS aren’t big proponents of widespread GLP-1 use for weight loss. We explore what it could mean for the obesity drug market amid a new administration.

Trump taps RFK Jr. to lead Health and Human Services: If confirmed, the vaccine skeptic’s appointment would hold serious implications for Big Pharma.

Biden Administration’s final rules aim to boost mental healthcare parity law: But with no new enforcement mechanisms in place, we’re bearish on their ability to improve patients’ access to mental healthcare in a meaningful way.

New gov’t tool tracks correlation between pollution, social health factors, and patient health: We explain what the government’s new Environmental Justice Index means for community health.

Cyberattacks on healthcare providers are surging, putting more pressure on them to protect their systems from breaches.

Interoperability has long been a pain point for the US healthcare system. While new federal regulations should spur payers and providers to adopt data-sharing solutions, ingrained information blocking practices, privacy concerns, and the demands of the pandemic may hamper efforts toward regulatory compliance.